Xolair from Novartis AG - asthma biologic extends into food allergy care

By Julian Reed, ad hoc news B2B & Pro Desk. Reviewed July 04, 2026, 9:15 AM ET. Details in the imprint.

Xolair (omalizumab) from Novartis AG sits in a refrigerated clinic fridge, a slim prefilled syringe inside a white box stamped with bold lettering and dose numbers. The nurse snaps on gloves, checks the label twice, and gives a quick subcutaneous injection in the upper arm before the patient heads back to work.

What Xolair is used for

Xolair is a monoclonal antibody biologic originally developed to treat moderate to severe persistent allergic asthma that is inadequately controlled with standard therapy. The drug targets immunoglobulin E (IgE), a key driver in many allergic responses, thereby helping reduce exacerbations and symptoms.

In the United States, Xolair is indicated for patients with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. It is also approved for chronic spontaneous urticaria in adults and adolescents and, more recently, to reduce allergic reactions from accidental exposure to certain foods in selected patients aged one year and older.

Biologic mechanism and dosing

Xolair contains omalizumab, a humanized monoclonal antibody that binds selectively to free IgE, preventing IgE from attaching to high-affinity receptors on mast cells and basophils. This reduces the likelihood of mediator release that leads to bronchoconstriction, hives, and other allergic symptoms. The mechanism differs from inhaled steroids or leukotriene modifiers, making Xolair part of a newer biologic class in asthma care.

Dosing for asthma and chronic spontaneous urticaria is based on body weight and baseline IgE levels, usually given as a subcutaneous injection every two or four weeks. Some patients receive Xolair via prefilled syringes administered in a clinic, while others use vials prepared by healthcare staff. The recent food allergy indication has a specific dosing schedule, and treatment must be combined with ongoing avoidance of trigger foods, not used as a license to eat allergens freely.

US availability and pricing

Xolair is widely available in the US through allergists, pulmonologists, and hospital outpatient centers. It is not typically stocked at retail pharmacies for consumer pickup, because administration is supervised due to the risk of anaphylaxis noted in the prescribing information. Physicians often enroll patients in manufacturer support programs that help navigate prior authorization and reimbursement.

List price for Xolair depends on dose strength and formulation, and public estimates typically range from several hundred to over a thousand dollars per injection before discounts. For commercially insured patients, out-of-pocket costs can vary widely based on plan design, copay assistance, and whether Xolair is billed as a pharmacy benefit or medical benefit. Medicare and some Medicaid programs may cover Xolair for approved indications, but coverage decisions depend on local policies and prior authorization criteria.

Growing role in food allergy

In February 2024, the US Food and Drug Administration approved Xolair for use in certain adults and children aged one year and older with food allergies, to reduce allergic reactions including anaphylaxis that may occur with accidental exposure to one or more foods. The approval was based on data showing fewer moderate to severe reactions when Xolair was used alongside strict avoidance.

Dr. David B. Peden, an allergist and trial investigator, has described omalizumab as a helpful tool in the broader management of food allergy, emphasizing that patients must continue to carry epinephrine and avoid allergenic foods even while on treatment. For families dealing with multiple severe food allergies, the possibility of a biologic that reduces reaction risk during accidental exposure is a significant clinical development, even though it does not cure allergy or replace standard precautions.

Clinical data and labeling considerations

The core asthma indication for Xolair relies on randomized trials showing reductions in asthma exacerbations and inhaled steroid requirements in patients with allergic asthma compared with standard therapy alone. Chronic spontaneous urticaria studies have demonstrated improved hive and itch scores for patients who had inadequate response to antihistamines, leading to broader adoption in dermatology and allergy clinics.

For the food allergy extension, pivotal trials included children and adults with multiple food allergies, who received Xolair and then underwent controlled food challenges to measure tolerance to accidental exposures. The FDA labeling stresses that patients still must avoid allergenic foods and that Xolair is not approved for emergency treatment of acute reactions. Serious adverse events in trials included anaphylaxis, which is reflected as a key warning in the prescribing information.

Safety profile and monitoring

Anaphylaxis is the most prominent serious safety concern associated with Xolair and can occur after any dose, including beyond the first injections. Because of this, patients are monitored in the clinic for a period following administration, and clinicians ensure that emergency equipment and trained staff are available. A boxed warning on the label summarizes the risk and the need for vigilance.

Other common adverse reactions include injection site reactions, headache, arthralgia, and nasopharyngitis. For chronic spontaneous urticaria, some patients report mild respiratory symptoms or gastrointestinal issues. The label also notes a potential risk of malignancy observed in some trials, though causality is not firmly established; physicians are advised to weigh benefits and risks individually and counsel patients accordingly.

Operational impact for US providers

From a provider operations standpoint, Xolair is a classic B2B biologic: clinics buy and bill the drug, and patients rarely see the product outside the treatment room. Practice managers negotiate reimbursement terms with payers to manage cash flow and avoid losses due to delayed or denied claims. Inventory management includes cold-chain handling and periodic checks to avoid wastage from expired vials or syringes.

Pulmonology and allergy practices also factor Xolair infusion or injection slots into their clinic schedules, bundling them with asthma control assessments and spirometry. Nurse practitioners and physician assistants play a central role: they educate patients about side effects, monitor post-injection reactions, and update electronic health records with dosing and IgE levels. Over time, workflow familiarity can make Xolair sessions relatively routine, despite the seriousness of the underlying conditions.

Competitive landscape in asthma biologics

Xolair competes in a crowded biologic field that includes anti-IL-5, anti-IL-4/13, and other targeted monoclonals aimed at severe asthma and allergic diseases. Products like dupilumab, mepolizumab, benralizumab, and reslizumab, marketed by other large pharma companies, give physicians multiple options for different phenotypes such as eosinophilic asthma or type 2 inflammation. IgE inhibition is one specific strategy among several, and choice depends on biomarkers, comorbidities, and payer formularies.

Novartis has repositioned Xolair in this context as a well-established option with expanding indications, particularly in allergy-related conditions where IgE plays a central role. The food allergy indication provides differentiation, since not all competitors have comparable approvals in that space. However, future pipeline products from rival firms may narrow that gap, and some academic centers are exploring combination strategies or stepwise sequencing of biologics.

Novartis portfolio context and stock

Within Novartis, Xolair is part of a broader immunology and respiratory portfolio that includes other biologics and small molecules, contributing to the company’s specialty-care revenue base. The product is co-marketed in some territories, and long-term real-world data continues to inform labeling updates and physician guidance. For US-focused investors, the FDA’s move into food allergy expands Xolair’s addressable patient population, though exact sales contributions are broken out alongside other immunology assets.

Novartis AG stock (NYSE: NVS, ISIN CH0012005267) reflects performance across oncology, cardiovascular, neuroscience, immunology, and generics, with Xolair forming one of several established biologic pillars rather than a single dominant revenue driver.

This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.

en | CH0012005267 | NOVARTIS | boerse | 69688489 | bgmi